Drug Discovery World

OCTOBER 3, 2022

As we sit on the cusp of the next wave of transformations made possible by quantum computing and rely ever more on external collaborations with the big tech companies how will this affect the current portfolio of global R&D facilities? Dr Yahya Anvar, Head of Data Science, OKRA.ai Fellowship Programme.

Drugs 52

Drugs Scientist Bioinformatics Medicine 52

Drug Discovery World

NOVEMBER 13, 2023

Stefan Ewert, PhD, Associate Director, Biologics Center, Novartis Institutes for Biomedical Research, on: ‘Computational counterselection identifies nonspecific therapeutic biologic candidates’. Hiroki Shirai, PhD, Coordinator, RIKEN Center for Computational Science, on: ‘Applying deep learning anomaly detection to antibody structures’.

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

NOVEMBER 9, 2023

The first three include: Sungjin Park, PhD, CEO, Onegene Biotechnology, on: ‘UniStac: Enzyme-mediated conjugation technology for accelerated development of tetraspecific NASH drug’. Iain Moal, PhD, Scientific Leader, Computational Antibody Engineering, GSK, on: ‘Learning antibody binding affinity using FACS and NGS’.

Engineer 52

Engineer Antibody Protein In-Vivo 52